文献速递糖尿病

GLP-1受体激动剂与糖尿病视网膜病变发病风险

Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.
PubMed 文献 · Diabetes Care · 2018-08-27

基于英国CPRD数据库的队列研究纳入77,115例2型糖尿病起始降糖药患者,随访245,825人年,10,763例新发糖尿病视网膜病变。与当前使用两种及以上口服降糖药相比,GLP-1受体激动剂使用与视网膜病变风险无显著增加相关(HR 1.00,95%CI 0.85-1.17)。与胰岛素相比,GLP-1受体激动剂与视网膜病变风险降低相关(HR 0.67,95%CI 0.51-0.90),作者认为可能由残余混杂所致。

要点

  • 与两种及以上口服降糖药相比,GLP-1受体激动剂不增加糖尿病视网膜病变风险(HR 1.00,95%CI 0.85-1.17)。
  • 与胰岛素相比,GLP-1受体激动剂与视网膜病变风险降低相关(HR 0.67,95%CI 0.51-0.90)。
  • 作者指出与胰岛素比较所得较低风险可能源于残余混杂。

核心结论

  • 与两种及以上口服降糖药相比,GLP-1受体激动剂使用与糖尿病视网膜病变发病风险无显著增加相关(HR 1.00,95%CI 0.85-1.17)。
  • 与胰岛素相比,GLP-1受体激动剂与视网膜病变风险降低相关(HR 0.67,95%CI 0.51-0.90),但作者认为可能由残余混杂所致。

研究设计与样本

  • 基于英国临床实践研究数据链(CPRD)的队列研究,纳入2007年1月至2015年9月间起始降糖药的77,115例2型糖尿病患者。
  • 采用时间依赖Cox比例风险模型估计校正风险比(HR)及95%CI,主要比较GLP-1受体激动剂与当前使用两种及以上口服降糖药,辅助分析比较GLP-1受体激动剂新使用者与胰岛素新使用者。

主要发现

  • 随访245,825人年期间,10,763例患者新诊断为糖尿病视网膜病变。
  • 与当前使用两种及以上口服降糖药相比,GLP-1受体激动剂使用与视网膜病变风险无显著增加相关(HR 1.00,95%CI 0.85-1.17)。
  • 与胰岛素相比,GLP-1受体激动剂与视网膜病变风险降低相关(HR 0.67,95%CI 0.51-0.90)。

临床怎么用

  • 与两种及以上口服降糖药相比,GLP-1受体激动剂不增加糖尿病视网膜病变风险。
  • 与胰岛素相比,GLP-1受体激动剂与视网膜病变风险降低相关,但作者认为该差异可能由残余混杂所致。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Previous studies suggested that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may initially worsen and possibly increase the risk of diabetic retinopathy. However, data on this possible association remain limited. Thus, this population-based study aimed to determine whether use of GLP-1 RAs is associated with an increased risk of incident diabetic retinopathy. RESEARCH DESIGN AND METHODS: Using the U.K. Clinical Practice Research Datalink (CPRD), we conducted a cohort study among 77,115 patients with type 2 diabetes initiating antidiabetic drugs between January 2007 and September 2015. Adjusted hazard ratios (HRs) and 95% CIs of incident diabetic retinopathy were estimated using time-dependent Cox proportional hazards models, comparing use of GLP-1 RAs with current use of two or more oral antidiabetic drugs. In an ancillary analysis, new users of GLP-1 RAs were compared with new users of insulin. RESULTS: During 245,825 person-years of follow-up, 10,763 patients were newly diagnosed with diabetic retinopathy. Compared with current use of two or more oral antidiabetic drugs, use of GLP-1 RAs was not associated with an increased risk of incident diabetic retinopathy overall (HR 1.00, 95% CI 0.85-1.17). Compared with insulin, GLP-1 RAs were associated with a decreased risk of diabetic retinopathy (HR 0.67, 95% CI 0.51-0.90). CONCLUSIONS: The associations with diabetic retinopathy varied according to the type of comparator. When compared with use of two or more oral antidiabetic drugs, use of GLP-1 RAs was not associated with an increased risk of incident diabetic retinopathy. The apparent lower risk of diabetic retinopathy associated with GLP-1 RAs compared with insulin may be due to residual confounding.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Douros A, Filion KB, Yin H, et al. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. Diabetes Care. 2018. PMID: 30150234. doi:10.2337/dc17-2280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。